Therapeutic Effect of Vitamin D3 in Multiple Sclerosis Patients

Autor:	Ali Ghazavi, Parviz Kokhaei, Keyvan Ghasami, Yahya Jand, Ghasem Mosayebi
Rok vydání:	2011
Předmět:	Adult Male Vitamin medicine.medical_specialty Multiple Sclerosis Adolescent T-Lymphocytes Immunology Lymphocyte Activation Placebo Injections Intramuscular Gastroenterology law.invention Interferon-gamma Young Adult chemistry.chemical_compound Calcitriol Double-Blind Method Randomized controlled trial Transforming Growth Factor beta law Internal medicine medicine Vitamin D and neurology Humans Phytohemagglutinins Cell Proliferation Cholecalciferol Expanded Disability Status Scale business.industry Multiple sclerosis Therapeutic effect General Medicine Middle Aged medicine.disease Interleukin-10 Treatment Outcome chemistry Leukocytes Mononuclear Female business Intramuscular injection
Zdroj:	Immunological Investigations. 40:627-639
ISSN:	1532-4311 0882-0139
DOI:	10.3109/08820139.2011.573041
Popis:	Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the central nervous system are damaged. The damage leads to demyelination and scarring as well as a broad spectrum of signs and symptoms. The epidemiological data suggest a possible influence of vitamin D as an immunomodulatory agent on multiple sclerosis susceptibility as well as on clinical course of the disease. We investigated the effects of short-term vitamin D3 therapy on Iranian patients with MS. In a prospective randomized controlled trial study, 62 MS patients received 300,000 IU/month vitamin D3 or placebo as intramuscular injection for 6 months. Our results showed no significant difference between the treatment and the control groups in the expanded disability status scale scores and number of gadolinium-enhancing lesions during the 6-month treatment period. After 6 months, the levels of cell proliferation in the vitamin D treatment group were significantly lower than the control group. Also, the levels of transforming growth factor-beta and interleukin-10 in the vitamin D treatment group were significantly higher than the control group. This result suggests that vitamin D therapy may help prevent the development of MS and could be a useful addition to the therapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9628750cf5a72d827c9c320ecaa435c6 https://doi.org/10.3109/08820139.2011.573041 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.